Otsuka Pharmaceutical Co., Ltd.
Vasopressin V2 Receptor Antagonist Samsca® 7.5mg Tablets To Be Launched in Japan on June 4 - Additional Choice of Dose for the Treatment of Volume Overload in Patients with Heart Failure
- Samsca 7.5mg tablets will become available for the treatment of volume overload in patients with congestive heart failure, in addition to the 15mg tablets, already available.
- The new dosage will be useful in cases where gradual increase of Samsca is desired, such as when it is used in elderly patients, or for those who show stronger aquaretic reaction to Samsca.
- It is estimated that there are approximately 1 million congestive heart failure patients with cardiac edema in Japan, out of which 220 thousand patients are hospitalized each year. Patient numbers are increasing with the aging of the population.
Tokyo, Japan, May 31, 2013 - Otsuka Pharmaceutical Co., Ltd. today announced that Samsca® (tolvaptan) 7.5mg tablets, vasopressin V2 receptor antagonist indicated for the treatment of volume overload in patients with heart failure, will be launched in Japan on June 4, 2013.